TrialThe Lancet. Oncology2025

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.

Sherko Kuemmel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.